HK Stock Market Move | XUANZHUBIO-B(02575) rose over 10% in morning trading and signed a licensing and supply agreement with Boston Oncology for Xuan Yuening and Xuan Feining.

XUANZHUBIO-B(02575) rose over 10% in early trading, up 9.96% at the time of publication to HK$34.46, with a trading volume of HK$3.4138 million. In terms of news, XUANZHUBIO-B announced that on April 9, 2026, the group (licensor) entered into a license and supply agreement (the Agreement) with Boston Oncology CGT Holding Co. Limited (licensee) regarding the drugs Piloselyl (trade name: XUANYUENING) and Delorak (trade name: XUANFEINING). Piloselyl is a CDK2/4/6 inhibitor independently developed by the group for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer; Delorak is a new generation anaplastic lymphoma kinase (ALK) inhibitor developed by the group for the treatment of ALK-positive advanced non-small cell lung cancer. Under the license and supply agreement, the licensor will grant the licensee an exclusive license to develop, register, and commercialize Piloselyl and Delorak in the authorized area (21 countries and regions in the Middle East and North Africa). The licensor will receive an upfront payment, potential regulatory and commercial milestone payments totaling over $100 million, and a fixed percentage royalty fee on sales in the authorized area. The licensor will supply the licensee with the products at agreed-upon prices to support the commercial development of both drugs in the authorized area.